"""种子数据：导入标签树 + 期刊列表 + 50 篇文献 + 文献标签关联"""

import asyncio
import json
import os
import sys
from datetime import date, datetime

from app.compat import UTC

sys.path.insert(0, os.path.join(os.path.dirname(__file__), '..'))

import uuid

from sqlalchemy import func, select

from app.core.security import hash_password
from app.db import async_session, engine
from app.models.business import DrugApproval, GuidelineEvidence, GuidelineVersion
from app.models.interaction import UserLiterature, UserNote, UserSubscription
from app.models.literature import GlobalJournal, GlobalLiterature, GlobalLiteratureTag, GlobalTag
from app.models.user import Tenant, User, UserTenant
from app.services.feed_engine import generate_all_feeds


def uid(): return uuid.uuid4()
def d(s): return date.fromisoformat(s) if s else None

async def import_tags():
    async with async_session() as db:
        existing = (await db.execute(select(func.count(GlobalTag.id)))).scalar() or 0
        if existing > 0:
            print(f"  Tags already exist ({existing}), skipping import")
            result = await db.execute(select(GlobalTag))
            tags = result.scalars().all()
            return {t.path: t.id for t in tags}

    with open(os.path.join(os.path.dirname(__file__), 'seed_oncology_tags.json'), encoding='utf-8') as f:
        tags_data = json.load(f)
    tags_data.sort(key=lambda x: x['level'])
    path_to_id: dict[str, str] = {}
    count = 0
    async with async_session() as db:
        for t in tags_data:
            parent_id = None
            if t.get('parent_path'): parent_id = path_to_id.get(t['parent_path'])
            tag = GlobalTag(id=uid(), name_zh=t['name_zh'], name_en=t.get('name_en'),
                path=t['path'], level=t['level'], parent_id=parent_id,
                tag_category=t['tag_category'], mesh_ui=t.get('mesh_ui'),
                is_selectable=(t['level'] <= 2))
            db.add(tag)
            path_to_id[t['path']] = tag.id
            count += 1
        await db.commit()
    print(f"  Tags imported: {count}")
    return path_to_id

async def import_journals():
    journals = [
        ("New England Journal of Medicine", "0028-4793", "1", 176.0),
        ("The Lancet", "0140-6736", "1", 98.4),
        ("JAMA", "0098-7484", "1", 63.1),
        ("BMJ", "0959-8138", "1", 93.6),
        ("Journal of Clinical Oncology", "0732-183X", "2", 42.1),
        ("Lancet Oncology", "1474-5488", "2", 51.0),
        ("JAMA Oncology", "2374-2437", "2", 28.7),
        ("Cancer Discovery", "2159-8290", "2", 29.5),
        ("Annals of Oncology", "0923-7534", "3", 48.0),
        ("Clinical Cancer Research", "1078-0432", "3", 11.5),
        ("Journal of the National Cancer Institute", "0027-8874", "3", 9.6),
        ("Cancer Cell", "1878-0261", "3", 48.8),
        ("European Journal of Cancer", "0959-8049", "3", 8.4),
        ("Cancer Research", "0008-5472", "3", 11.2),
        ("Nature Medicine", "1078-8956", "2", 82.9),
        ("Nature Cancer", "2662-1347", "3", 22.3),
        ("Cancer", "0008-543X", "4", 6.2),
        ("Blood", "0006-4971", "4", 21.0),
        ("Leukemia", "0887-6924", "4", 11.4),
        ("Int J Radiat Oncol Biol Phys", "0360-3016", "4", 7.0),
        ("Journal of the NCCN", "1540-1405", "4", 11.0),
        ("Journal of Thoracic Oncology", "1556-0864", "4", 12.5),
        ("Lung Cancer", "0169-5002", "4", 5.0),
    ]
    async with async_session() as db:
        for name, issn, tier, if_ in journals:
            db.add(GlobalJournal(id=uid(), name=name, issn=issn, tier=tier, impact_factor=if_, publisher="—"))
        await db.commit()
    print(f"  Journals imported: {len(journals)}")

async def import_literature(tag_map: dict[str, str]):
    """每篇文献附带标签路径列表，自动关联"""
    articles = [
        {"pmid": 39000101,
         "title": "Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC: Final OS Results from FLAURA2",
         "abstract": "Osimertinib plus chemotherapy vs osimertinib alone in EGFR-mutated NSCLC. Median OS 42.1 vs 35.8 mo, HR 0.73.",
         "authors": [{"family": "Ramalingam", "given": "SS", "affiliation": "Winship Cancer Institute, Emory University"}, {"family": "Cheng", "given": "Y", "affiliation": "Jilin Cancer Hospital"}, {"family": "Zhou", "given": "C", "affiliation": "Guangdong Provincial People's Hospital"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-07-03", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "终点::OS", "场景::一线"]},
        {"pmid": 39000102,
         "title": "Atezolizumab SC vs IV in Advanced NSCLC: IMscin002",
         "abstract": "Subcutaneous atezolizumab showed comparable efficacy and safety vs IV formulation in pretreated NSCLC.",
         "authors": [{"family": "Burotto", "given": "M", "affiliation": "Bradford Hill Clinical Research Center"}, {"family": "Zvirbule", "given": "Z", "affiliation": "Riga East University Hospital"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2025-07-01", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-L1", "研究类型::RCT::2期", "终点::安全性"]},
        {"pmid": 39000103,
         "title": "Trastuzumab Deruxtecan vs Physician's Choice in HER2-Low mBC: DESTINY-Breast06",
         "abstract": "T-DXd superior PFS vs chemo in HER2-low and HER2-ultralow metastatic breast cancer.",
         "authors": [{"family": "Curigliano", "given": "G", "affiliation": "European Institute of Oncology, Milan"}, {"family": "Hu", "given": "X", "affiliation": "Fudan University Shanghai Cancer Center"}, {"family": "Dent", "given": "RA", "affiliation": "National Cancer Centre Singapore"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-06-28", "pub_year": 2025,
         "tag_paths": ["癌种::乳腺癌", "靶点::HER2", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "终点::PFS"]},
        {"pmid": 39000104,
         "title": "Pembrolizumab plus Chemotherapy in Advanced Biliary Tract Cancer: KEYNOTE-966",
         "abstract": "Pembrolizumab plus gem/cis improved OS in advanced BTC vs chemo alone.",
         "authors": [{"family": "Kelley", "given": "RK"}, {"family": "Ueno", "given": "M"}],
         "journal": "The Lancet", "journal_issn": "0140-6736",
         "pub_date": "2025-06-25", "pub_year": 2025,
         "tag_paths": ["治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "终点::OS", "场景::一线"]},
        {"pmid": 39000105,
         "title": "Toripalimab plus Chemotherapy as First-Line Treatment for ESCC: JUPITER-06",
         "abstract": "Toripalimab plus chemo improved OS and PFS in advanced ESCC vs chemo alone.",
         "authors": [{"family": "Xu", "given": "JM"}, {"family": "Li", "given": "J"}],
         "journal": "JAMA", "journal_issn": "0098-7484",
         "pub_date": "2025-06-20", "pub_year": 2025,
         "tag_paths": ["癌种::食管癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "终点::OS", "场景::一线"]},
        {"pmid": 39000106,
         "title": "Adjuvant Alectinib vs Chemotherapy in ALK-Positive NSCLC: ALINA Updated OS",
         "abstract": "Adjuvant alectinib showed sustained DFS benefit vs chemo in resected ALK+ NSCLC.",
         "authors": [{"family": "Solomon", "given": "BJ"}, {"family": "Wu", "given": "YL"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-06-15", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::辅助"]},
        {"pmid": 39000107,
         "title": "Neoadjuvant Dostarlimab in dMMR Locally Advanced Rectal Cancer: 3-Year Results",
         "abstract": "100% clinical complete response maintained at 3 years with PD-1 blockade alone in dMMR LARC.",
         "authors": [{"family": "Cercek", "given": "A"}, {"family": "Lumish", "given": "M"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-06-10", "pub_year": 2025,
         "tag_paths": ["癌种::结直肠癌", "靶点::MSI", "治疗::免疫治疗::PD-1", "场景::新辅助", "终点::ORR"]},
        {"pmid": 39000108,
         "title": "Palbociclib plus Endocrine Therapy vs Chemotherapy in HR+/HER2- mBC",
         "abstract": "CDK4/6 inhibitor plus ET showed comparable OS to chemo with better QoL in first-line mBC.",
         "authors": [{"family": "Llombart-Cussac", "given": "A"}, {"family": "Perez-Garcia", "given": "JM"}],
         "journal": "Annals of Oncology", "journal_issn": "0923-7534",
         "pub_date": "2025-06-08", "pub_year": 2025,
         "tag_paths": ["癌种::乳腺癌::HR阳性", "靶点::PIK3CA", "治疗::内分泌治疗", "研究类型::RCT::3期", "终点::OS", "场景::一线"]},
        {"pmid": 39000109,
         "title": "ctDNA-Guided Adjuvant Chemotherapy in Stage II Colon Cancer: DYNAMIC",
         "abstract": "ctDNA-informed approach reduced chemo use by 50% without compromising 2-year RFS.",
         "authors": [{"family": "Tie", "given": "J"}, {"family": "Cohen", "given": "JD"}],
         "journal": "Lancet Oncology", "journal_issn": "1474-5488",
         "pub_date": "2025-06-05", "pub_year": 2025,
         "tag_paths": ["癌种::结直肠癌", "终点::生物标志物", "场景::辅助", "研究类型::转化研究"]},
        {"pmid": 39000110,
         "title": "Cilta-cel vs Standard of Care in Lenalidomide-Refractory MM: CARTITUDE-4",
         "abstract": "CAR-T cilta-cel significantly improved PFS and OS vs standard triplet in len-refractory MM.",
         "authors": [{"family": "San-Miguel", "given": "J"}, {"family": "Usmani", "given": "SZ"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-06-01", "pub_year": 2025,
         "tag_paths": ["癌种::血液肿瘤::多发性骨髓瘤", "治疗::免疫治疗::CAR-T", "研究类型::RCT::3期", "终点::OS"]},
        {"pmid": 39000111,
         "title": "Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible mUC",
         "abstract": "EV+pembro improved OS and PFS vs gem/carbo in first-line cisplatin-ineligible mUC.",
         "authors": [{"family": "Powles", "given": "T"}, {"family": "Gupta", "given": "S"}],
         "journal": "JAMA Oncology", "journal_issn": "2374-2437",
         "pub_date": "2025-05-28", "pub_year": 2025,
         "tag_paths": ["癌种::膀胱癌", "治疗::靶向治疗::ADC", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线"]},
        {"pmid": 39000112,
         "title": "Sotorasib plus Panitumumab vs Standard in KRAS G12C mCRC: CodeBreaK 300",
         "abstract": "KRAS G12C inhibitor plus EGFR antibody improved PFS vs standard in pretreated mCRC.",
         "authors": [{"family": "Fakih", "given": "MG"}, {"family": "Kopetz", "given": "S"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-05-25", "pub_year": 2025,
         "tag_paths": ["癌种::结直肠癌", "靶点::KRAS", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::二线"]},
        {"pmid": 39000113,
         "title": "Nivolumab in Resected Stage IIB/C Melanoma: CheckMate 76K Final",
         "abstract": "Adjuvant nivo showed durable RFS benefit in resected high-risk stage II melanoma.",
         "authors": [{"family": "Long", "given": "GV"}, {"family": "Tawbi", "given": "HA"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2025-05-22", "pub_year": 2025,
         "tag_paths": ["癌种::黑色素瘤", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::辅助"]},
        {"pmid": 39000114,
         "title": "Perioperative Durvalumab in Resectable NSCLC: AEGEAN 5Y",
         "abstract": "Perioperative durvalumab improved EFS and OS in resectable NSCLC at 5 years.",
         "authors": [{"family": "Heymach", "given": "JV"}, {"family": "Mitsudomi", "given": "T"}],
         "journal": "Lancet Oncology", "journal_issn": "1474-5488",
         "pub_date": "2025-05-18", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-L1", "研究类型::RCT::3期", "场景::新辅助", "终点::OS"]},
        {"pmid": 39000115,
         "title": "Amivantamab plus Lazertinib vs Osimertinib in EGFR-mutant NSCLC: MARIPOSA",
         "abstract": "Ami+laz showed superior PFS vs osi in tx-naive EGFR-mutant NSCLC.",
         "authors": [{"family": "Cho", "given": "BC"}, {"family": "Lu", "given": "S"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-05-15", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "靶点::MET", "治疗::靶向治疗::双特异性抗体", "研究类型::RCT::3期", "场景::一线"]},
        {"pmid": 39000116,
         "title": "Sacituzumab Govitecan vs Docetaxel in HR+/HER2- mBC: TROPiCS-02 Final OS",
         "abstract": "Trop-2 ADC improved OS in endocrine-resistant, chemotherapy-treated HR+/HER2- mBC.",
         "authors": [{"family": "Rugo", "given": "HS"}, {"family": "Bardia", "given": "A"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2025-05-12", "pub_year": 2025,
         "tag_paths": ["癌种::乳腺癌::HR阳性", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "终点::OS", "场景::二线"]},
        {"pmid": 39000117,
         "title": "Nivo+Ipi vs Chemo in dMMR/MSI-H mCRC: CheckMate 8HW",
         "abstract": "Dual immunotherapy significantly improved PFS vs chemo in dMMR/MSI-H mCRC.",
         "authors": [{"family": "Lenz", "given": "HJ"}, {"family": "Van Cutsem", "given": "E"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-05-08", "pub_year": 2025,
         "tag_paths": ["癌种::结直肠癌", "靶点::MSI", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::一线"]},
        {"pmid": 39000118,
         "title": "SABR vs Standard RT in Oligometastatic NSCLC: SABR-COMET-10",
         "abstract": "SABR improved OS and PFS in pts with 4-10 oligometastatic NSCLC lesions.",
         "authors": [{"family": "Palma", "given": "DA"}, {"family": "Olson", "given": "R"}],
         "journal": "The Lancet", "journal_issn": "0140-6736",
         "pub_date": "2025-05-05", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::放疗::SBRT", "场景::寡转移", "终点::OS"]},
        {"pmid": 39000119,
         "title": "Datopotamab Deruxtecan vs Docetaxel in Advanced NSCLC: TROPION-Lung01",
         "abstract": "Dato-DXd showed numerically improved PFS and favorable safety vs docetaxel in pretreated NSCLC.",
         "authors": [{"family": "Ahn", "given": "MJ"}, {"family": "Paz-Ares", "given": "L"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2025-05-01", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "场景::二线", "终点::PFS"]},
        {"pmid": 39000120,
         "title": "NCCN Guidelines: NSCLC Version 5.2025",
         "abstract": "Updated NCCN guidelines for NSCLC: osimertinib+chemo category 1; amivantamab+lazertinib added.",
         "authors": [{"family": "Ettinger", "given": "DS"}, {"family": "Wood", "given": "DE"}],
         "journal": "Journal of the NCCN", "journal_issn": "1540-1405",
         "pub_date": "2025-05-01", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "研究类型::指南", "场景::一线"]},
        {"pmid": 39000121,
         "title": "Fruquintinib plus Paclitaxel in Advanced Gastric Cancer: FRUTIGA",
         "abstract": "Fruquintinib plus paclitaxel significantly improved PFS in pretreated advanced GC/GEJC.",
         "authors": [{"family": "Wang", "given": "FH"}, {"family": "Shen", "given": "L"}],
         "journal": "Annals of Oncology", "journal_issn": "0923-7534",
         "pub_date": "2025-04-28", "pub_year": 2025,
         "tag_paths": ["癌种::胃癌", "治疗::抗血管生成", "研究类型::RCT::3期", "场景::二线", "终点::PFS"]},
        {"pmid": 39000122,
         "title": "Long-Term Follow-up of CAR-T in r/r ALL: ELIANA 5-Year",
         "abstract": "Tisagenlecleucel showed durable remissions with 55% 5-year EFS in pediatric/young adult r/r B-ALL.",
         "authors": [{"family": "Maude", "given": "SL"}, {"family": "Laetsch", "given": "TW"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-04-25", "pub_year": 2025,
         "tag_paths": ["癌种::血液肿瘤::白血病", "治疗::免疫治疗::CAR-T", "终点::OS", "终点::生物标志物"]},
        {"pmid": 39000123,
         "title": "Neoadjuvant Pembrolizumab+Chemotherapy in Early TNBC: KEYNOTE-522 Final",
         "abstract": "Pembro neoadjuvant/adjuvant in TNBC confirmed sustained EFS and OS benefit at 5 years.",
         "authors": [{"family": "Schmid", "given": "P"}, {"family": "Cortes", "given": "J"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-04-22", "pub_year": 2025,
         "tag_paths": ["癌种::乳腺癌::三阴性乳腺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::新辅助", "终点::OS"]},
        {"pmid": 39000124,
         "title": "Lenvatinib plus Pembrolizumab vs Sunitinib in aRCC: CLEAR 5Y",
         "abstract": "Lenva+pembro maintained OS and PFS advantage over sunitinib in 1L aRCC at 5 years.",
         "authors": [{"family": "Motzer", "given": "RJ"}, {"family": "Porta", "given": "C"}],
         "journal": "Lancet Oncology", "journal_issn": "1474-5488",
         "pub_date": "2025-04-18", "pub_year": 2025,
         "tag_paths": ["癌种::肾癌", "治疗::靶向治疗::TKI", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000125,
         "title": "Brigatinib vs Crizotinib in ALK+ NSCLC: ALTA-1L Final OS",
         "abstract": "Brigatinib showed OS trend favoring vs crizotinib with reduced CNS progression.",
         "authors": [{"family": "Camidge", "given": "DR"}, {"family": "Kim", "given": "HR"}],
         "journal": "Journal of Thoracic Oncology", "journal_issn": "1556-0864",
         "pub_date": "2025-04-15", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "终点::OS"]},
        {"pmid": 39000126,
         "title": "Systematic Review: PD-1/PD-L1 Inhibitors in MSI-H Solid Tumors",
         "abstract": "Meta-analysis of 45 trials: PD-1/PD-L1 inhibitors 38% pooled ORR across MSI-H tumors.",
         "authors": [{"family": "Andre", "given": "T"}, {"family": "Cohen", "given": "R"}],
         "journal": "Cancer Discovery", "journal_issn": "2159-8290",
         "pub_date": "2025-04-12", "pub_year": 2025,
         "tag_paths": ["靶点::MSI", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::PD-L1", "研究类型::Meta分析", "终点::ORR"]},
        {"pmid": 39000127,
         "title": "Tucatinib+Trastuzumab+Capecitabine in HER2+ mBC with Brain Mets: HER2CLIMB-02",
         "abstract": "Tucatinib-based triplet improved intracranial PFS and OS in HER2+ BC with brain mets.",
         "authors": [{"family": "Lin", "given": "NU"}, {"family": "Murthy", "given": "RK"}],
         "journal": "JAMA Oncology", "journal_issn": "2374-2437",
         "pub_date": "2025-04-08", "pub_year": 2025,
         "tag_paths": ["癌种::乳腺癌::HER2阳性", "靶点::HER2", "治疗::靶向治疗::TKI", "研究类型::RCT::2期", "终点::OS"]},
        {"pmid": 39000128,
         "title": "Maintenance Olaparib in gBRCA-Mutated mPC: POLO Final OS",
         "abstract": "Olaparib maintenance showed OS numerical improvement in gBRCA-mutated metastatic pancreatic cancer.",
         "authors": [{"family": "Golan", "given": "T"}, {"family": "Hammel", "given": "P"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2025-04-05", "pub_year": 2025,
         "tag_paths": ["癌种::胰腺癌", "靶点::BRCA", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::维持", "终点::OS"]},
        {"pmid": 39000129,
         "title": "AI-Based Prediction of Neoadjuvant Chemotherapy Response in Breast Cancer",
         "abstract": "Deep learning on H&E slides predicted pCR AUC 0.92 in external validation across 3 cohorts.",
         "authors": [{"family": "Sammut", "given": "SJ"}, {"family": "Crispin-Ortuzar", "given": "M"}],
         "journal": "Nature Medicine", "journal_issn": "1078-8956",
         "pub_date": "2025-04-02", "pub_year": 2025,
         "tag_paths": ["癌种::乳腺癌", "场景::新辅助", "治疗::化疗", "终点::生物标志物", "研究类型::转化研究"]},
        {"pmid": 39000130,
         "title": "Repotrectinib in ROS1-Positive Advanced NSCLC: TRIDENT-1 Updated",
         "abstract": "Repotrectinib showed durable responses in TKI-naive and pretreated ROS1+ NSCLC, including CNS.",
         "authors": [{"family": "Drilon", "given": "A"}, {"family": "Cho", "given": "BC"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-03-30", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ROS1", "治疗::靶向治疗::TKI", "终点::ORR", "终点::PFS"]},
        {"pmid": 39000131,
         "title": "Zanidatamab in Previously Treated HER2+ Biliary Tract Cancer: HERIZON-BTC-01",
         "abstract": "HER2 bispecific Ab showed meaningful ORR and durable responses in HER2+ BTC.",
         "authors": [{"family": "Harding", "given": "JJ"}, {"family": "Piha-Paul", "given": "S"}],
         "journal": "Lancet Oncology", "journal_issn": "1474-5488",
         "pub_date": "2025-03-27", "pub_year": 2025,
         "tag_paths": ["靶点::HER2", "治疗::靶向治疗::双特异性抗体", "研究类型::RCT::2期", "终点::ORR"]},
        {"pmid": 39000132,
         "title": "Ivosidenib plus Azacitidine in IDH1-Mutant AML: AGILE Final",
         "abstract": "IDH1 inhibitor plus AZA showed OS improvement in newly diagnosed IDH1-mutant AML.",
         "authors": [{"family": "Montesinos", "given": "P"}, {"family": "Recher", "given": "C"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-03-25", "pub_year": 2025,
         "tag_paths": ["癌种::血液肿瘤::白血病", "靶点::IDH", "治疗::靶向治疗", "研究类型::RCT::3期", "终点::OS"]},
        {"pmid": 39000133,
         "title": "Pembro in BCG-Unresponsive NMIBC: KEYNOTE-057 Final",
         "abstract": "Pembro showed durable CR in high-risk NMIBC. 36-month CR rate: 22%.",
         "authors": [{"family": "Balar", "given": "AV"}, {"family": "Kamat", "given": "AM"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2025-03-22", "pub_year": 2025,
         "tag_paths": ["癌种::膀胱癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::2期", "终点::ORR"]},
        {"pmid": 39000134,
         "title": "Liquid Biopsy for MRD Detection in CRC: GALAXY Study",
         "abstract": "ctDNA-based MRD detection post-surgery strongly predicted recurrence in stage II-III CRC (HR 11.3).",
         "authors": [{"family": "Kotani", "given": "D"}, {"family": "Oki", "given": "E"}],
         "journal": "Nature Medicine", "journal_issn": "1078-8956",
         "pub_date": "2025-03-18", "pub_year": 2025,
         "tag_paths": ["癌种::结直肠癌", "终点::生物标志物", "场景::辅助", "研究类型::转化研究"]},
        {"pmid": 39000135,
         "title": "Selpercatinib in RET Fusion-Positive Solid Tumors: LIBRETTO-001 Pan-Tumor",
         "abstract": "RET inhibitor showed 44% ORR across RET fusion+ non-lung/non-thyroid solid tumors.",
         "authors": [{"family": "Subbiah", "given": "V"}, {"family": "Wolf", "given": "J"}],
         "journal": "Cancer Discovery", "journal_issn": "2159-8290",
         "pub_date": "2025-03-15", "pub_year": 2025,
         "tag_paths": ["靶点::RET", "治疗::靶向治疗::TKI", "终点::ORR"]},
        {"pmid": 39000136,
         "title": "First-Line Atezo/Bev in Advanced HCC: IMbrave150 5-Year OS",
         "abstract": "Atezo/Bev maintained OS benefit at 5 years in advanced HCC (HR 0.66).",
         "authors": [{"family": "Finn", "given": "RS"}, {"family": "Qin", "given": "S"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-03-12", "pub_year": 2025,
         "tag_paths": ["癌种::肝癌::肝细胞癌", "治疗::免疫治疗::PD-L1", "治疗::抗血管生成", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000137,
         "title": "Darolutamide + ADT vs ADT alone in mHSPC: ARASENS 5-Year",
         "abstract": "Triplet therapy with darolutamide+ADT+docetaxel continued OS improvement vs ADT+docetaxel.",
         "authors": [{"family": "Smith", "given": "MR"}, {"family": "Hussain", "given": "M"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-03-08", "pub_year": 2025,
         "tag_paths": ["癌种::前列腺癌", "治疗::内分泌治疗", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000138,
         "title": "Durvalumab+Tremelimumab in 1L HCC: HIMALAYA 4-Year OS",
         "abstract": "STRIDE regimen showed sustained OS improvement. 4-year OS: 25.2% vs 18.5% with sorafenib.",
         "authors": [{"family": "Abou-Alfa", "given": "GK"}, {"family": "Lau", "given": "G"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2025-03-05", "pub_year": 2025,
         "tag_paths": ["癌种::肝癌::肝细胞癌", "治疗::免疫治疗::PD-L1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000139,
         "title": "Adagrasib plus Cetuximab vs Chemotherapy in KRAS G12C mCRC: KRYSTAL-1",
         "abstract": "Adagrasib+cetuximab improved ORR (34% vs 6%) and PFS vs standard in pretreated KRAS G12C mCRC.",
         "authors": [{"family": "Yaeger", "given": "R"}, {"family": "Weiss", "given": "J"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-03-01", "pub_year": 2025,
         "tag_paths": ["癌种::结直肠癌", "靶点::KRAS", "治疗::靶向治疗", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
        {"pmid": 39000140,
         "title": "Real-World PD-1 Inhibitors in Chinese Patients with Advanced NSCLC",
         "abstract": "In 8,423 real-world patients, PD-1 inhibitors median OS 18.5mo vs 12.1mo with chemo alone.",
         "authors": [{"family": "Wu", "given": "YL"}, {"family": "Zhou", "given": "Q"}],
         "journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
         "pub_date": "2025-02-28", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::真实世界", "终点::OS"]},
        {"pmid": 39000141,
         "title": "ESMO Guidelines: HCC Diagnosis, Treatment and Follow-up",
         "abstract": "Updated ESMO guidelines: 1L atezo+bev or durva+treme; 2L options expanded.",
         "authors": [{"family": "Vogel", "given": "A"}, {"family": "Cervantes", "given": "A"}],
         "journal": "Annals of Oncology", "journal_issn": "0923-7534",
         "pub_date": "2025-02-25", "pub_year": 2025,
         "tag_paths": ["癌种::肝癌::肝细胞癌", "研究类型::指南", "场景::一线", "场景::二线"]},
        {"pmid": 39000142,
         "title": "Adjuvant Pembrolizumab in Muscle-Invasive Urothelial Carcinoma: AMBASSADOR",
         "abstract": "Adjuvant pembro improved DFS vs observation in high-risk MIUC after radical surgery.",
         "authors": [{"family": "Apolo", "given": "AB"}, {"family": "Ballman", "given": "KV"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-02-22", "pub_year": 2025,
         "tag_paths": ["癌种::膀胱癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::辅助"]},
        {"pmid": 39000143,
         "title": "Tepotinib in MET Exon 14 Skipping NSCLC: VISION Final",
         "abstract": "MET inhibitor tepotinib showed durable responses in METex14 NSCLC across lines, including elderly.",
         "authors": [{"family": "Paik", "given": "PK"}, {"family": "Felip", "given": "E"}],
         "journal": "JAMA Oncology", "journal_issn": "2374-2437",
         "pub_date": "2025-02-18", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::MET", "治疗::靶向治疗::TKI", "研究类型::RCT::2期", "终点::ORR"]},
        {"pmid": 39000144,
         "title": "Neoadjuvant Nivolumab+Chemo in Resectable Gastric Cancer: DANTE",
         "abstract": "Adding nivo to FLOT improved pCR rate in resectable GC.",
         "authors": [{"family": "Al-Batran", "given": "SE"}, {"family": "Lorenzen", "given": "S"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2025-02-15", "pub_year": 2025,
         "tag_paths": ["癌种::胃癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::2期", "场景::新辅助", "终点::ORR"]},
        {"pmid": 39000145,
         "title": "Lorlatinib vs Crizotinib in 1L ALK+ Advanced NSCLC: CROWN 5-Year PFS",
         "abstract": "Lorlatinib showed unprecedented 5-year PFS of 60% vs 8% with crizotinib in ALK+ NSCLC.",
         "authors": [{"family": "Solomon", "given": "BJ"}, {"family": "Bauer", "given": "TM"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2025-02-10", "pub_year": 2025,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000146,
         "title": "Mutation-Targeted Neoadjuvant Therapy in Pancreatic Cancer",
         "abstract": "Germline/somatic mutation-guided neoadjuvant therapy improved R0 resection rate in LAPC (62% vs 35%).",
         "authors": [{"family": "O'Reilly", "given": "EM"}, {"family": "Yu", "given": "KH"}],
         "journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
         "pub_date": "2025-02-05", "pub_year": 2025,
         "tag_paths": ["癌种::胰腺癌", "靶点::BRCA", "治疗::靶向治疗", "场景::新辅助", "研究类型::真实世界"]},
        {"pmid": 39000147,
         "title": "Pembro in Advanced Endometrial Cancer: KEYNOTE-775 Biomarker Analysis",
         "abstract": "PD-L1 CPS and TMB independently predicted response to pembro+lenvatinib in EC.",
         "authors": [{"family": "Makker", "given": "V"}, {"family": "Colombo", "given": "N"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2025-02-01", "pub_year": 2025,
         "tag_paths": ["癌种::妇科肿瘤::子宫内膜癌", "靶点::TMB", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "终点::生物标志物"]},
        {"pmid": 39000148,
         "title": "AI-Assisted Colonoscopy for CRC Screening: Meta-Analysis of 21 RCTs",
         "abstract": "AI-assisted colonoscopy increased ADR by 24% and reduced miss rate by 50%.",
         "authors": [{"family": "Hassan", "given": "C"}, {"family": "Spadaccini", "given": "M"}],
         "journal": "The Lancet", "journal_issn": "0140-6736",
         "pub_date": "2025-01-28", "pub_year": 2025,
         "tag_paths": ["癌种::结直肠癌", "研究类型::Meta分析", "终点::生物标志物"]},
        {"pmid": 39000149,
         "title": "Bemarituzumab plus mFOLFOX6 in FGFR2b GC: FIGHT Final",
         "abstract": "FGFR2b-targeted antibody plus chemo improved OS in FGFR2b-overexpressing GC.",
         "authors": [{"family": "Wainberg", "given": "ZA"}, {"family": "Enzinger", "given": "PC"}],
         "journal": "JAMA Oncology", "journal_issn": "2374-2437",
         "pub_date": "2025-01-25", "pub_year": 2025,
         "tag_paths": ["癌种::胃癌", "靶点::FGFR", "治疗::靶向治疗", "研究类型::RCT::3期", "终点::OS"]},
        {"pmid": 39000150,
         "title": "mRNA-4157 (V940) plus Pembrolizumab in High-Risk Melanoma: KEYNOTE-942",
         "abstract": "Personalized mRNA vaccine plus pembro reduced recurrence risk by 49% vs pembro alone in resected melanoma.",
         "authors": [{"family": "Weber", "given": "JS"}, {"family": "Carlino", "given": "MS"}],
         "journal": "The Lancet", "journal_issn": "0140-6736",
         "pub_date": "2025-01-20", "pub_year": 2025,
         "tag_paths": ["癌种::黑色素瘤", "治疗::免疫治疗::PD-1", "研究类型::RCT::2期", "场景::辅助", "终点::PFS"]},
        # ── 近日文献（用于首页测试） ──
        {"pmid": 39000201,
         "title": "Alectinib in ALK-Positive Early-Stage NSCLC: ALINA Updated CNS Analysis",
         "abstract": "Alectinib demonstrated superior CNS DFS vs chemo in resected ALK+ NSCLC, with 4-year CNS DFS 98%.",
         "authors": [{"family": "Solomon", "given": "BJ", "affiliation": "Peter MacCallum Cancer Centre, Melbourne"}, {"family": "Wu", "given": "YL", "affiliation": "Guangdong Provincial People's Hospital"}, {"family": "John", "given": "T", "affiliation": "Austin Health"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "doi": "10.1056/NEJMoa2400381", "pmc_id": "PMC11223344", "is_oa": True, "cited_by_count": 24,
         "pub_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase III"],
         "pub_date": "2026-07-06", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::辅助", "终点::PFS"]},
        {"pmid": 39000202,
         "title": "Enfortumab Vedotin + Pembrolizumab in Untreated Advanced Urothelial Carcinoma: EV-302 Final OS",
         "abstract": "EV+pembro combination continued to show significant OS benefit over chemo in 1L advanced UC at final analysis.",
         "authors": [{"family": "Powles", "given": "T", "affiliation": "Barts Cancer Institute, London"}, {"family": "Rosenberg", "given": "JE", "affiliation": "Memorial Sloan Kettering"}, {"family": "Sonpavde", "given": "GP", "affiliation": "AdventHealth Cancer Institute"}],
         "journal": "JAMA Oncology", "journal_issn": "2374-2437",
         "doi": "10.1001/jamaoncol.2024.1234", "cited_by_count": 18,
         "pub_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase III"],
         "pub_date": "2026-07-06", "pub_year": 2026,
         "tag_paths": ["癌种::膀胱癌", "治疗::靶向治疗::ADC", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000203,
         "title": "Trastuzumab Deruxtecan in HER2-Mutant Advanced NSCLC: DESTINY-Lung02 5-Year Update",
         "abstract": "T-DXd continued to show durable responses in HER2-mutant NSCLC with median DoR 18.6 months.",
         "authors": [{"family": "Li", "given": "BT", "affiliation": "Memorial Sloan Kettering Cancer Center"}, {"family": "Smit", "given": "EF", "affiliation": "Netherlands Cancer Institute"}, {"family": "Goto", "given": "Y", "affiliation": "National Cancer Center Hospital, Tokyo"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "doi": "10.1200/JCO.24.00123",
         "pub_types": ["Journal Article", "Clinical Trial, Phase II"],
         "pub_date": "2026-07-05", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::HER2", "治疗::靶向治疗::ADC", "研究类型::RCT::2期", "终点::ORR"]},
        {"pmid": 39000204,
         "title": "Pembrolizumab plus Chemoradiotherapy in Locally Advanced Cervical Cancer: KEYNOTE-A18 Updated",
         "abstract": "Pembro plus chemoradiotherapy improved PFS in locally advanced cervical cancer, benefit consistent across subgroups.",
         "authors": [{"family": "Lorusso", "given": "D", "affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milan"}, {"family": "Colombo", "given": "N", "affiliation": "University of Milan"}, {"family": "Tewari", "given": "KS", "affiliation": "University of California, Irvine"}],
         "journal": "The Lancet", "journal_issn": "0140-6736",
         "doi": "10.1016/S0140-6736(24)01568-2", "cited_by_count": 42,
         "pub_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase III"],
         "pub_date": "2026-07-05", "pub_year": 2026,
         "tag_paths": ["癌种::妇科肿瘤::宫颈癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000205,
         "title": "Lorlatinib in ALK-Positive Advanced NSCLC: CROWN 6-Year PFS Analysis",
         "abstract": "Updated CROWN analysis: lorlatinib showed 62% 6-year PFS in 1L ALK+ NSCLC, with sustained CNS protection.",
         "authors": [{"family": "Solomon", "given": "BJ", "affiliation": "Peter MacCallum Cancer Centre"}, {"family": "Bauer", "given": "TM", "affiliation": "Sarah Cannon Research Institute"}, {"family": "Mok", "given": "TS", "affiliation": "The Chinese University of Hong Kong"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "doi": "10.1056/NEJMoa2405681", "pmc_id": "PMC11223345", "is_oa": True, "cited_by_count": 56,
         "pub_types": ["Journal Article", "Randomized Controlled Trial", "Clinical Trial, Phase III"],
         "pub_date": "2026-07-04", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000206,
         "title": "Belantamab Mafodotin + Pomalidomide + Dex in Relapsed/Refractory MM: DREAMM-8",
         "abstract": "Belantamab mafodotin triplet significantly improved PFS vs pomalidomide+dex in RRMM, HR 0.52.",
         "authors": [{"family": "Dimopoulos", "given": "MA"}, {"family": "Beksac", "given": "M"}, {"family": "Pour", "given": "L"}],
         "journal": "Blood", "journal_issn": "0006-4971",
         "doi": "10.1182/blood.2024026481",
         "pub_date": "2026-07-03", "pub_year": 2026,
         "tag_paths": ["癌种::血液肿瘤::多发性骨髓瘤", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "场景::二线", "终点::PFS"]},
        {"pmid": 39000207,
         "title": "Neoadjuvant Nivolumab Relatlimab in Resectable Melanoma: RELATIVITY-098",
         "abstract": "Neoadjuvant nivo+rela improved event-free survival vs surgery alone in resectable stage III melanoma.",
         "authors": [{"family": "Long", "given": "GV"}, {"family": "Mandalà", "given": "M"}, {"family": "Lebbé", "given": "C"}],
         "journal": "JAMA", "journal_issn": "0098-7484",
         "doi": "10.1001/jama.2024.12345",
         "pub_date": "2026-07-03", "pub_year": 2026,
         "tag_paths": ["癌种::黑色素瘤", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::新辅助", "终点::PFS"]},
        {"pmid": 39000208,
         "title": "FOLFIRINOX versus Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer: NAPOLEON-3",
         "abstract": "Modified FOLFIRINOX showed numerically superior OS vs gem+nap in mPC; tolerability favored the control arm.",
         "authors": [{"family": "Conroy", "given": "T"}, {"family": "Desseigne", "given": "F"}, {"family": "Ychou", "given": "M"}],
         "journal": "The Lancet Oncology", "journal_issn": "1474-5488",
         "doi": "10.1016/S1470-2045(24)00567-1",
         "pub_date": "2026-07-01", "pub_year": 2026,
         "tag_paths": ["癌种::胰腺癌", "治疗::化疗", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000209,
         "title": "Sotorasib + Panitumumab vs Chemo in KRAS G12C mCRC: CodeBreaK 300 Final OS",
         "abstract": "Sotorasib+panitumumab maintained OS benefit vs standard in chemorefractory KRAS G12C mCRC.",
         "authors": [{"family": "Fakih", "given": "MG"}, {"family": "Kopetz", "given": "S"}, {"family": "Kim", "given": "TW"}],
         "journal": "Annals of Oncology", "journal_issn": "0923-7534",
         "doi": "10.1016/j.annonc.2024.06.012",
         "pub_date": "2026-06-30", "pub_year": 2026,
         "tag_paths": ["癌种::结直肠癌", "靶点::KRAS", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
        {"pmid": 39000210,
         "title": "Zanidatamab in Previously Treated HER2+ Colorectal Cancer: Phase 2 Update",
         "abstract": "Zanidatamab, a HER2 bispecific antibody, showed promising ORR of 38% in pretreated HER2+ mCRC.",
         "authors": [{"family": "Siena", "given": "S"}, {"family": "Sartore-Bianchi", "given": "A"}, {"family": "Marsh", "given": "S"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "doi": "10.1200/JCO.24.00987",
         "pub_date": "2026-06-30", "pub_year": 2026,
         "tag_paths": ["癌种::结直肠癌", "靶点::HER2", "治疗::靶向治疗::双特异性抗体", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
        # ── 更多测试数据（用于翻页测试） ──
        {"pmid": 39000301,
         "title": "Tislelizumab plus Chemotherapy in Advanced NSCLC: RATIONALE-307 5-Year Update",
         "abstract": "Long-term follow-up confirms OS benefit of tislelizumab+chemo in 1L advanced squamous NSCLC.",
         "authors": [{"family": "Wang", "given": "J"}, {"family": "Zhou", "given": "C"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2026-06-25", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000302,
         "title": "Sintilimab plus Chemo vs Chemo in Advanced ESCC: ORIENT-15 Final OS",
         "abstract": "Sintilimab plus chemo showed sustained OS benefit in advanced ESCC across PD-L1 subgroups.",
         "authors": [{"family": "Xu", "given": "RH"}, {"family": "Song", "given": "Y"}],
         "journal": "BMJ", "journal_issn": "0959-8138",
         "pub_date": "2026-06-22", "pub_year": 2026,
         "tag_paths": ["癌种::食管癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000303,
         "title": "Camrelizumab plus Rivoceranib in Advanced HCC: CARES-310 Updated",
         "abstract": "Camrelizumab+rivoceranib maintained OS and PFS benefit in 1L advanced HCC; QoL analysis favorable.",
         "authors": [{"family": "Qin", "given": "S"}, {"family": "Chan", "given": "SL"}],
         "journal": "The Lancet", "journal_issn": "0140-6736",
         "pub_date": "2026-06-20", "pub_year": 2026,
         "tag_paths": ["癌种::肝癌::肝细胞癌", "治疗::免疫治疗::PD-1", "治疗::抗血管生成", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000304,
         "title": "Serplulimab plus Chemo in ES-SCLC: ASTRUM-005 3-Year OS",
         "abstract": "PD-1 inhibitor serplulimab+chemo showed sustained 3-year OS benefit in extensive-stage SCLC.",
         "authors": [{"family": "Cheng", "given": "Y"}, {"family": "Han", "given": "L"}],
         "journal": "JAMA", "journal_issn": "0098-7484",
         "pub_date": "2026-06-18", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000305,
         "title": "Penpulimab plus Chemo in Advanced NSCLC: AK105-302",
         "abstract": "Penpulimab plus carboplatin+paclitaxel improved PFS in 1L advanced squamous NSCLC.",
         "authors": [{"family": "Ma", "given": "Z"}, {"family": "Zhang", "given": "L"}],
         "journal": "Lung Cancer", "journal_issn": "0169-5002",
         "pub_date": "2026-06-15", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000306,
         "title": "Surufatinib vs Placebo in Advanced Pancreatic Neuroendocrine Tumors: SANET-p",
         "abstract": "Surufatinib improved PFS in advanced pancreatic NETs with manageable safety profile.",
         "authors": [{"family": "Xu", "given": "J"}, {"family": "Shen", "given": "L"}],
         "journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
         "pub_date": "2026-06-12", "pub_year": 2026,
         "tag_paths": ["癌种::胰腺癌", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000307,
         "title": "Adjuvant Osimertinib in Resected EGFR-Mutant NSCLC: ADAURA 7-Year OS",
         "abstract": "ADAURA 7-year OS update: adjuvant osimertinib HR 0.49 for OS in stage IB-IIIA EGFR-mutant NSCLC.",
         "authors": [{"family": "Herbst", "given": "RS"}, {"family": "Wu", "given": "YL"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2026-06-10", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::辅助", "终点::OS"]},
        {"pmid": 39000308,
         "title": "Talazoparib plus Enzalutamide in mCRPC: TALAPRO-2 Final OS",
         "abstract": "PARP inhibitor talazoparib+enzalutamide OS benefit confirmed in HRR-mutated mCRPC.",
         "authors": [{"family": "Agarwal", "given": "N"}, {"family": "Azad", "given": "AA"}],
         "journal": "The Lancet", "journal_issn": "0140-6736",
         "pub_date": "2026-06-08", "pub_year": 2026,
         "tag_paths": ["癌种::前列腺癌", "靶点::BRCA", "治疗::靶向治疗::PARP抑制剂", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000309,
         "title": "First-Line Nivolumab plus Ipilimumab in MSI-H mCRC: CheckMate 8HW 4-Year",
         "abstract": "Nivo+ipi maintained PFS benefit at 4-year follow-up in MSI-H/dMMR mCRC, with high complete response rate.",
         "authors": [{"family": "Lenz", "given": "HJ"}, {"family": "Yoshino", "given": "T"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2026-06-05", "pub_year": 2026,
         "tag_paths": ["癌种::结直肠癌", "靶点::MSI", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000310,
         "title": "Ribociclib plus Endocrine Therapy in Early HR+/HER2- BC: NATALEE Updated",
         "abstract": "Ribociclib+NSA IDFS benefit across stage II-III HR+/HER2- early breast cancer.",
         "authors": [{"family": "Slamon", "given": "DJ"}, {"family": "Fasching", "given": "PA"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2026-06-02", "pub_year": 2026,
         "tag_paths": ["癌种::乳腺癌::HR阳性", "靶点::PIK3CA", "治疗::靶向治疗::CDK4/6抑制剂", "研究类型::RCT::3期", "场景::辅助", "终点::PFS"]},
        {"pmid": 39000311,
         "title": "Pembrolizumab plus Lenvatinib in Advanced Endometrial Cancer: KEYNOTE-775 Final OS",
         "abstract": "Pembro+lenva OS benefit sustained in pMMR advanced EC at final analysis.",
         "authors": [{"family": "Makker", "given": "V"}, {"family": "Aghajanian", "given": "C"}],
         "journal": "JAMA Oncology", "journal_issn": "2374-2437",
         "pub_date": "2026-05-30", "pub_year": 2026,
         "tag_paths": ["癌种::妇科肿瘤::子宫内膜癌", "治疗::靶向治疗::TKI", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000312,
         "title": "Anti-PD-1 in Nasopharyngeal Carcinoma: JUPITER-02 5-Year OS",
         "abstract": "Toripalimab+chemo 5-year OS rate 52% vs 33% with chemo alone in recurrent/metastatic NPC.",
         "authors": [{"family": "Mai", "given": "HQ"}, {"family": "Chen", "given": "QY"}],
         "journal": "Nature Medicine", "journal_issn": "1078-8956",
         "pub_date": "2026-05-28", "pub_year": 2026,
         "tag_paths": ["癌种::头颈肿瘤::鼻咽癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000313,
         "title": "Crizotinib vs Chemo in ALK+ NSCLC: PROFILE 1029 10-Year Follow-Up",
         "abstract": "10-year follow-up of crizotinib in Asian ALK+ NSCLC: median OS 52.3mo vs 38.5mo for chemo.",
         "authors": [{"family": "Wu", "given": "YL"}, {"family": "Lu", "given": "S"}],
         "journal": "Journal of Thoracic Oncology", "journal_issn": "1556-0864",
         "pub_date": "2026-05-25", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::ALK", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000314,
         "title": "Avapritinib in Advanced GIST: NAVIGATOR 5-Year Update",
         "abstract": "Long-term avapritinib shows durable responses in PDGFRA D842V-mutant and KIT-mutant GIST.",
         "authors": [{"family": "Heinrich", "given": "MC"}, {"family": "Jones", "given": "RL"}],
         "journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
         "pub_date": "2026-05-22", "pub_year": 2026,
         "tag_paths": ["癌种::消化道肿瘤::GIST", "靶点::KIT", "治疗::靶向治疗::TKI", "研究类型::RCT::2期", "终点::ORR"]},
        {"pmid": 39000315,
         "title": "Vismodegib in Basal Cell Carcinoma: 8-Year Follow-Up",
         "abstract": "Longest follow-up of hedgehog inhibitor in advanced BCC: median DoR 26.2 months, 5-year OS 48%.",
         "authors": [{"family": "Sekulic", "given": "A"}, {"family": "Migden", "given": "MR"}],
         "journal": "Cancer Discovery", "journal_issn": "2159-8290",
         "pub_date": "2026-05-20", "pub_year": 2026,
         "tag_paths": ["癌种::皮肤肿瘤", "靶点::Hedgehog", "治疗::靶向治疗", "研究类型::单臂", "终点::OS"]},
        {"pmid": 39000316,
         "title": "Nivolumab in Relapsed Malignant Mesothelioma: CONFIRM 3-Year OS",
         "abstract": "Nivo improved OS in relapsed mesothelioma; benefit seen in both epithelioid and non-epithelioid subtypes.",
         "authors": [{"family": "Fennell", "given": "DA"}, {"family": "Porter", "given": "C"}],
         "journal": "The Lancet", "journal_issn": "0140-6736",
         "pub_date": "2026-05-18", "pub_year": 2026,
         "tag_paths": ["癌种::间皮瘤", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
        {"pmid": 39000317,
         "title": "Pomalidomide and Daratumumab in RRMM: Updated Real-World Evidence",
         "abstract": "Real-world study of 1200+ RRMM patients: pomalidomide+daratumumab triplet ORR 71%, median PFS 16.4mo.",
         "authors": [{"family": "Richardson", "given": "PG"}, {"family": "Bahlis", "given": "NJ"}],
         "journal": "Blood", "journal_issn": "0006-4971",
         "pub_date": "2026-05-15", "pub_year": 2026,
         "tag_paths": ["癌种::血液肿瘤::多发性骨髓瘤", "治疗::靶向治疗", "治疗::免疫治疗", "研究类型::真实世界", "场景::二线", "终点::PFS"]},
        {"pmid": 39000318,
         "title": "ESMO Guidelines: Management of Metastatic Colorectal Cancer 2026",
         "abstract": "Updated ESMO mCRC guidelines: immunotherapy priority in MSI-H; RAS/BRAF testing expanded; TAS-102+bev new standard.",
         "authors": [{"family": "Cervantes", "given": "A"}, {"family": "Van Cutsem", "given": "E"}],
         "journal": "Annals of Oncology", "journal_issn": "0923-7534",
         "pub_date": "2026-05-12", "pub_year": 2026,
         "tag_paths": ["癌种::结直肠癌", "研究类型::指南", "场景::一线", "场景::二线", "终点::OS"]},
        {"pmid": 39000319,
         "title": "Lurbinectedin + Doxorubicin in Relapsed SCLC: Phase 2 Basket Trial",
         "abstract": "Lurbinectedin+doxorubicin ORR 42% in relapsed SCLC, including chemo-resistant patients.",
         "authors": [{"family": "Paz-Ares", "given": "L"}, {"family": "Trigo", "given": "JM"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2026-05-10", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::小细胞肺癌", "治疗::化疗", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
        {"pmid": 39000320,
         "title": "Trastuzumab Deruxtecan in HER2-Low Biliary Tract Cancer: Phase 2",
         "abstract": "T-DXd demonstrated ORR of 32% in previously treated HER2-low BTC, with median DoR 11.3mo.",
         "authors": [{"family": "Oh", "given": "DY"}, {"family": "Lee", "given": "CK"}],
         "journal": "Lancet Oncology", "journal_issn": "1474-5488",
         "pub_date": "2026-05-08", "pub_year": 2026,
         "tag_paths": ["癌种::胆管癌", "靶点::HER2", "治疗::靶向治疗::ADC", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
        {"pmid": 39000321,
         "title": "Nivolumab plus Ipilimumab in Advanced HCC: CheckMate 9DW 5-Year",
         "abstract": "Nivo+ipi sustained OS benefit vs lenva/sorafenib in 1L advanced HCC at 5-year landmark analysis.",
         "authors": [{"family": "Yau", "given": "T"}, {"family": "Kudo", "given": "M"}],
         "journal": "JAMA Oncology", "journal_issn": "2374-2437",
         "pub_date": "2026-05-05", "pub_year": 2026,
         "tag_paths": ["癌种::肝癌::肝细胞癌", "治疗::免疫治疗::PD-1", "治疗::免疫治疗::CTLA-4", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000322,
         "title": "Entrectinib in NTRK Fusion-Positive Solid Tumors: Integrated Analysis",
         "abstract": "Entrectinib showed 57% ORR across 14 tumor types with NTRK fusions; CNS ORR 50%.",
         "authors": [{"family": "Doebele", "given": "RC"}, {"family": "Drilon", "given": "A"}],
         "journal": "Cancer Discovery", "journal_issn": "2159-8290",
         "pub_date": "2026-05-02", "pub_year": 2026,
         "tag_paths": ["靶点::NTRK", "治疗::靶向治疗::TKI", "终点::ORR"]},
        {"pmid": 39000323,
         "title": "Ipatasertib plus Paclitaxel in PIK3CA-Mutant Breast Cancer: IPATunity130",
         "abstract": "AKT inhibitor ipatasertib+chemo improved PFS in PIK3CA-mutant advanced TNBC.",
         "authors": [{"family": "Schmid", "given": "P"}, {"family": "Cortes", "given": "J"}],
         "journal": "Nature Medicine", "journal_issn": "1078-8956",
         "pub_date": "2026-04-30", "pub_year": 2026,
         "tag_paths": ["癌种::乳腺癌::三阴性乳腺癌", "靶点::PIK3CA", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000324,
         "title": "Claudin18.2-Targeted CAR-T in Advanced GI Cancers: Phase 1 Update",
         "abstract": "CLDN18.2 CAR-T cell therapy showed 48% ORR in advanced gastric and pancreatic cancers.",
         "authors": [{"family": "Qi", "given": "C"}, {"family": "Gong", "given": "J"}],
         "journal": "Nature Medicine", "journal_issn": "1078-8956",
         "pub_date": "2026-04-28", "pub_year": 2026,
         "tag_paths": ["癌种::胃癌", "靶点::CLDN18.2", "治疗::免疫治疗::CAR-T", "研究类型::RCT::1期", "场景::二线", "终点::ORR"]},
        {"pmid": 39000325,
         "title": "Bispecific Antibodies in Multiple Myeloma: Systematic Review and Meta-Analysis",
         "abstract": "Meta-analysis of 24 trials: BCMA bispecifics pooled ORR 63% in RRMM; CRS rate 55% mostly grade 1-2.",
         "authors": [{"family": "Anderson", "given": "KC"}, {"family": "Munshi", "given": "NC"}],
         "journal": "Blood", "journal_issn": "0006-4971",
         "pub_date": "2026-04-25", "pub_year": 2026,
         "tag_paths": ["癌种::血液肿瘤::多发性骨髓瘤", "靶点::BCMA", "治疗::免疫治疗::双特异性抗体", "研究类型::Meta分析", "终点::ORR"]},
        {"pmid": 39000326,
         "title": "Tucatinib in HER2+ CRC with Brain Metastases: MOUNTAINEER Update",
         "abstract": "Tucatinib+trastuzumab showed intracranial ORR 29% in HER2+ mCRC with brain metastases.",
         "authors": [{"family": "Strickler", "given": "JH"}, {"family": "Yoshino", "given": "T"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2026-04-22", "pub_year": 2026,
         "tag_paths": ["癌种::结直肠癌", "靶点::HER2", "治疗::靶向治疗::TKI", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
        {"pmid": 39000327,
         "title": "Adjuvant Pembrolizumab in RCC: KEYNOTE-564 5-Year OS",
         "abstract": "Adjuvant pembro in high-risk RCC: DFS benefit maintained at 5 years, OS trending favorable.",
         "authors": [{"family": "Choueiri", "given": "TK"}, {"family": "Tomczak", "given": "P"}],
         "journal": "The Lancet Oncology", "journal_issn": "1474-5488",
         "pub_date": "2026-04-20", "pub_year": 2026,
         "tag_paths": ["癌种::肾癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::辅助", "终点::OS"]},
        {"pmid": 39000328,
         "title": "Darolutamide plus ADT in High-Risk Biochemically Recurrent PC: ARAMIS 7-Year",
         "abstract": "Darolutamide+ADT improved metastasis-free survival and OS in high-risk BCR at 7-year analysis.",
         "authors": [{"family": "Fizazi", "given": "K"}, {"family": "Shore", "given": "N"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2026-04-18", "pub_year": 2026,
         "tag_paths": ["癌种::前列腺癌", "治疗::内分泌治疗", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000329,
         "title": "Osimertinib in Unresectable Stage III EGFR-Mutant NSCLC: LAURA Updated",
         "abstract": "LAURA update: osimertinib PFS benefit confirmed in unresectable stage III EGFR-mutant NSCLC post-CRT.",
         "authors": [{"family": "Lu", "given": "S"}, {"family": "Kato", "given": "T"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2026-04-15", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "治疗::靶向治疗::TKI", "研究类型::RCT::3期", "场景::维持", "终点::PFS"]},
        {"pmid": 39000330,
         "title": "Mirvetuximab Soravtansine in FRα+ Ovarian Cancer: SORAYA 3-Year",
         "abstract": "FRα-targeting ADC mirvetuximab maintained ORR of 32% in FRα-high platinum-resistant ovarian cancer.",
         "authors": [{"family": "Matulonis", "given": "UA"}, {"family": "Oaknin", "given": "A"}],
         "journal": "JAMA Oncology", "journal_issn": "2374-2437",
         "pub_date": "2026-04-12", "pub_year": 2026,
         "tag_paths": ["癌种::妇科肿瘤::卵巢癌", "靶点::FRα", "治疗::靶向治疗::ADC", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
        {"pmid": 39000331,
         "title": "Avelumab in Merkel Cell Carcinoma: JAVELIN Merkel 200 5-Year",
         "abstract": "Avelumab 5-year OS rate 28% in mMCC; responses associated with PD-L1 expression and TMB.",
         "authors": [{"family": "D'Angelo", "given": "SP"}, {"family": "Bhatia", "given": "S"}],
         "journal": "Cancer Discovery", "journal_issn": "2159-8290",
         "pub_date": "2026-04-10", "pub_year": 2026,
         "tag_paths": ["癌种::皮肤肿瘤", "治疗::免疫治疗::PD-L1", "研究类型::RCT::2期", "终点::OS"]},
        {"pmid": 39000332,
         "title": "Zenocutuzumab in NRG1 Fusion-Positive Solid Tumors: Phase 2",
         "abstract": "HER2/HER3 bispecific antibody showed ORR 34% across NRG1 fusion+ pancreatic, NSCLC, and other tumors.",
         "authors": [{"family": "Schram", "given": "AM"}, {"family": "O'Reilly", "given": "EM"}],
         "journal": "Cancer Discovery", "journal_issn": "2159-8290",
         "pub_date": "2026-04-08", "pub_year": 2026,
         "tag_paths": ["靶点::NRG1", "治疗::靶向治疗::双特异性抗体", "研究类型::RCT::2期", "终点::ORR"]},
        {"pmid": 39000333,
         "title": "Giredestrant vs Letrozole in ER+ Advanced Breast Cancer: acelERA",
         "abstract": "Oral SERD giredestrant showed comparable PFS to letrozole in ER+/HER2- advanced BC with favorable safety.",
         "authors": [{"family": "Martin", "given": "M"}, {"family": "Bardia", "given": "A"}],
         "journal": "Annals of Oncology", "journal_issn": "0923-7534",
         "pub_date": "2026-04-05", "pub_year": 2026,
         "tag_paths": ["癌种::乳腺癌::HR阳性", "治疗::内分泌治疗", "研究类型::RCT::2期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000334,
         "title": "Capecitabine Maintenance in Advanced Nasopharyngeal Carcinoma: Phase 3",
         "abstract": "Capecitabine maintenance after chemo improved PFS in advanced NPC (median 18.5 vs 11.8 mo).",
         "authors": [{"family": "Chen", "given": "YP"}, {"family": "Tang", "given": "LL"}],
         "journal": "BMJ", "journal_issn": "0959-8138",
         "pub_date": "2026-04-02", "pub_year": 2026,
         "tag_paths": ["癌种::头颈肿瘤::鼻咽癌", "治疗::化疗", "研究类型::RCT::3期", "场景::维持", "终点::PFS"]},
        {"pmid": 39000335,
         "title": "Selinexor in KRAS-Mutant Advanced NSCLC: Phase 2 Study",
         "abstract": "XPO1 inhibitor selinexor showed clinical activity in KRAS-mutant NSCLC, ORR 10%, DCR 58%.",
         "authors": [{"family": "Skoulidis", "given": "F"}, {"family": "Govindan", "given": "R"}],
         "journal": "Journal of Thoracic Oncology", "journal_issn": "1556-0864",
         "pub_date": "2026-03-30", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::KRAS", "研究类型::RCT::2期", "场景::二线", "终点::ORR"]},
        {"pmid": 39000336,
         "title": "Sacituzumab Govitecan in Advanced UC: TROPiCS-04 Final",
         "abstract": "Trop-2 ADC sacituzumab govitecan showed OS benefit vs standard in platinum-refractory advanced UC.",
         "authors": [{"family": "Tagawa", "given": "ST"}, {"family": "Balar", "given": "AV"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2026-03-28", "pub_year": 2026,
         "tag_paths": ["癌种::膀胱癌", "治疗::靶向治疗::ADC", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
        {"pmid": 39000337,
         "title": "First-Line Atezolizumab in PD-L1+ NSCLC: IMPower110 5-Year",
         "abstract": "Atezo monotherapy 5-year OS rate in PD-L1-high 1L NSCLC: 25% vs 17% with chemo.",
         "authors": [{"family": "Herbst", "given": "RS"}, {"family": "Giaccone", "given": "G"}],
         "journal": "JAMA Oncology", "journal_issn": "2374-2437",
         "pub_date": "2026-03-25", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-L1", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000338,
         "title": "Targeted Therapy in NSCLC with Rare Driver Mutations: Chinese Real-World Study",
         "abstract": "Real-world analysis of 3200+ NSCLC patients: 12% harbored rare drivers; targeted therapy improved outcomes over chemo.",
         "authors": [{"family": "Zhou", "given": "Q"}, {"family": "Wu", "given": "YL"}],
         "journal": "Clinical Cancer Research", "journal_issn": "1078-0432",
         "pub_date": "2026-03-22", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::EGFR", "靶点::ALK", "靶点::ROS1", "研究类型::真实世界", "终点::OS"]},
        {"pmid": 39000339,
         "title": "TAS-102 plus Bevacizumab in Refractory mCRC: SUNLIGHT 3-Year",
         "abstract": "TAS-102+bev maintained OS benefit at 3 years in chemorefractory mCRC; HR 0.61.",
         "authors": [{"family": "Prager", "given": "GW"}, {"family": "Taieb", "given": "J"}],
         "journal": "The Lancet Oncology", "journal_issn": "1474-5488",
         "pub_date": "2026-03-20", "pub_year": 2026,
         "tag_paths": ["癌种::结直肠癌", "治疗::化疗", "治疗::抗血管生成", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
        {"pmid": 39000340,
         "title": "Metastatic Castration-Sensitive Prostate Cancer: Treatment Intensification Patterns",
         "abstract": "Real-world study of 4500+ mCSPC patients: triplet therapy adoption growing; ARAT+ADT+docetaxel improved outcomes.",
         "authors": [{"family": "Ryan", "given": "CJ"}, {"family": "Agarwal", "given": "N"}],
         "journal": "European Journal of Cancer", "journal_issn": "0959-8049",
         "pub_date": "2026-03-18", "pub_year": 2026,
         "tag_paths": ["癌种::前列腺癌", "治疗::内分泌治疗", "治疗::化疗", "研究类型::真实世界", "场景::一线", "终点::OS"]},
        {"pmid": 39000341,
         "title": "Tabelecleucel in EBV+ PTLD: Phase 3 ALLELE Trial",
         "abstract": "EBV-specific T-cell therapy tabelecleucel improved OS in EBV+ post-transplant lymphoproliferative disease.",
         "authors": [{"family": "Ptushkin", "given": "VN"}, {"family": "Nikiforow", "given": "S"}],
         "journal": "Blood", "journal_issn": "0006-4971",
         "pub_date": "2026-03-15", "pub_year": 2026,
         "tag_paths": ["癌种::血液肿瘤::淋巴瘤", "治疗::免疫治疗", "研究类型::RCT::3期", "终点::OS"]},
        {"pmid": 39000342,
         "title": "Sotorasib in KRAS G12C NSCLC: CodeBreaK 100 5-Year Outcomes",
         "abstract": "5-year pooled analysis of sotorasib in KRAS G12C NSCLC: median OS 12.5mo in pretreated patients.",
         "authors": [{"family": "Janne", "given": "PA"}, {"family": "Riely", "given": "GJ"}],
         "journal": "New England Journal of Medicine", "journal_issn": "0028-4793",
         "pub_date": "2026-03-12", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "靶点::KRAS", "治疗::靶向治疗", "研究类型::RCT::2期", "场景::二线", "终点::OS"]},
        {"pmid": 39000343,
         "title": "Ibrutinib in CLL: RESONATE-2 10-Year Follow-Up",
         "abstract": "10-year follow-up: ibrutinib PFS rate 43% in 1L CLL; sustained OS benefit vs chlorambucil.",
         "authors": [{"family": "Burger", "given": "JA"}, {"family": "Barr", "given": "PM"}],
         "journal": "Blood", "journal_issn": "0006-4971",
         "pub_date": "2026-03-10", "pub_year": 2026,
         "tag_paths": ["癌种::血液肿瘤::白血病", "靶点::BTK", "治疗::靶向治疗::BTK抑制剂", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000344,
         "title": "Nivolumab in Advanced Squamous NSCLC: CheckMate 017 8-Year OS",
         "abstract": "8-year OS rate with nivo in advanced squamous NSCLC: 12% vs 4% with docetaxel.",
         "authors": [{"family": "Spigel", "given": "DR"}, {"family": "Brahmer", "given": "JR"}],
         "journal": "Journal of Clinical Oncology", "journal_issn": "0732-183X",
         "pub_date": "2026-03-08", "pub_year": 2026,
         "tag_paths": ["癌种::肺癌::非小细胞肺癌", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::二线", "终点::OS"]},
        {"pmid": 39000345,
         "title": "Adjuvant Encorafenib+Bini in BRAF-Mutant Stage III Melanoma: COLUMBUS 7-Year",
         "abstract": "Adjuvant encorafenib+binimetinib sustained RFS benefit in BRAF V600-mutant stage III melanoma at 7 years.",
         "authors": [{"family": "Robert", "given": "C"}, {"family": "Dummer", "given": "R"}],
         "journal": "JAMA", "journal_issn": "0098-7484",
         "pub_date": "2026-03-05", "pub_year": 2026,
         "tag_paths": ["癌种::黑色素瘤", "靶点::BRAF", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::辅助", "终点::PFS"]},
        {"pmid": 39000346,
         "title": "Pembrolizumab in MSI-H/dMMR CRC: KEYNOTE-177 5-Year Final",
         "abstract": "Pembro 5-year PFS rate 34% vs 13% with chemo in 1L MSI-H/dMMR mCRC; OS HR 0.71.",
         "authors": [{"family": "Andre", "given": "T"}, {"family": "Shiu", "given": "KK"}],
         "journal": "The Lancet Oncology", "journal_issn": "1474-5488",
         "pub_date": "2026-03-02", "pub_year": 2026,
         "tag_paths": ["癌种::结直肠癌", "靶点::MSI", "治疗::免疫治疗::PD-1", "研究类型::RCT::3期", "场景::一线", "终点::PFS"]},
        {"pmid": 39000347,
         "title": "Zolbetuximab plus mFOLFOX6 in CLDN18.2+ GC: SPOTLIGHT Updated",
         "abstract": "Zolbetuximab+chemo PFS and OS benefit confirmed in CLDN18.2+, HER2- advanced GC at updated analysis.",
         "authors": [{"family": "Shah", "given": "MA"}, {"family": "Xu", "given": "RH"}],
         "journal": "Nature Medicine", "journal_issn": "1078-8956",
         "pub_date": "2026-02-28", "pub_year": 2026,
         "tag_paths": ["癌种::胃癌", "靶点::CLDN18.2", "治疗::靶向治疗", "研究类型::RCT::3期", "场景::一线", "终点::OS"]},
        {"pmid": 39000348,
         "title": "T-DXd in HER2-Overexpressing Solid Tumors: DESTINY-PanTumor02",
         "abstract": "T-DXd showed ORR 37% across HER2 IHC3+ solid tumors; median DoR 11.8 months in basket trial.",
         "authors": [{"family": "Meric-Bernstam", "given": "F"}, {"family": "Hamilton", "given": "EP"}],
         "journal": "Cancer Discovery", "journal_issn": "2159-8290",
         "pub_date": "2026-02-25", "pub_year": 2026,
         "tag_paths": ["靶点::HER2", "治疗::靶向治疗::ADC", "研究类型::RCT::2期", "终点::ORR"]},
        {"pmid": 39000349,
         "title": "Vosoritide in Achondroplasia: Phase 3 Final Results",
         "abstract": "Vosoritide increased annualized growth velocity in children with achondroplasia; safety consistent with prior data.",
         "authors": [{"family": "Savarirayan", "given": "R"}, {"family": "Tofts", "given": "L"}],
         "journal": "The Lancet", "journal_issn": "0140-6736",
         "pub_date": "2026-02-22", "pub_year": 2026,
         "tag_paths": ["研究类型::RCT::3期", "终点::安全性"]},
        {"pmid": 39000350,
         "title": "CSCO Guidelines: Breast Cancer Treatment 2026",
         "abstract": "Updated CSCO BC guidelines: CDK4/6 inhibitor adjuvant indication expanded; ADC in HER2-low updated recommendations.",
         "authors": [{"family": "Jiang", "given": "ZF"}, {"family": "Li", "given": "JY"}],
         "journal": "European Journal of Cancer", "journal_issn": "0959-8049",
         "pub_date": "2026-02-20", "pub_year": 2026,
         "tag_paths": ["癌种::乳腺癌", "研究类型::指南", "场景::一线", "场景::辅助"]},
    ]

    async with async_session() as db:
        lit_count, tag_count = 0, 0
        for a in articles:
            existing = await db.execute(select(GlobalLiterature.id).where(GlobalLiterature.pmid == a['pmid']))
            if existing.scalar(): continue

            lit = GlobalLiterature(id=uid(), pmid=a['pmid'], title=a['title'], abstract=a['abstract'],
                authors=a['authors'], journal=a.get('journal'), journal_issn=a.get('journal_issn'),
                doi=a.get('doi'), pub_date=d(a.get('pub_date')), pub_year=a.get('pub_year'),
                pub_types=a.get('pub_types', []), mesh_headings=[], source="seed_data",
                pmc_id=a.get('pmc_id'), is_oa=a.get('is_oa', False),
                cited_by_count=a.get('cited_by_count', 0))
            db.add(lit)
            await db.flush()
            lit_count += 1

            # 关联标签
            for path in a.get('tag_paths', []):
                tag_id = tag_map.get(path)
                if tag_id:
                    db.add(GlobalLiteratureTag(literature_id=lit.id, tag_id=tag_id, is_major=True))
                    tag_count += 1

        await db.commit()
    print(f"  Literature: {lit_count} articles, {tag_count} tag associations")

async def main():
    print("=== Seeding Data ===")
    # 使用 Alembic 迁移建表（保证与生产 schema 一致）
    import subprocess, sys
    _backend = os.path.dirname(os.path.dirname(__file__))
    _r = subprocess.run(
        [sys.executable, "-m", "alembic", "-c", "alembic/alembic.ini", "upgrade", "head"],
        cwd=_backend, capture_output=True, text=True,
    )
    if _r.returncode != 0:
        print("  Alembic migration failed:", _r.stderr)
        sys.exit(1)
    print("  Tables migrated")
    tag_map = await import_tags()
    await import_journals()
    await import_literature(tag_map)

    # 创建 Demo 用户 + 订阅 + Feed
    print("  Creating demo user...")
    async with async_session() as db:
        demo = User(id=uid(), email="demo@test.cn", hashed_password=hash_password("123456"),
                     display_name="王主任", title="主任医师")
        db.add(demo)
        tenant = Tenant(id=uid(), name="王主任的个人空间",
                         slug="demo-tenant", hospital_name="北京协和医院",
                         department_name="肿瘤内科", plan_type="team")
        db.add(tenant)
        await db.flush()
        db.add(UserTenant(id=uid(), user_id=demo.id, tenant_id=tenant.id, role="owner", is_default=True))
        await db.flush()

        # 订阅主要癌种 + 治疗方式 + 研究类型（覆盖约 90% 的测试文献，确保翻页测试有足够 Feed）
        for tag_path in [
            "癌种::肺癌::非小细胞肺癌", "癌种::乳腺癌", "癌种::结直肠癌", "癌种::胃癌",
            "癌种::肝癌::肝细胞癌", "癌种::食管癌", "癌种::胰腺癌", "癌种::前列腺癌",
            "癌种::膀胱癌", "癌种::肾癌", "癌种::黑色素瘤", "癌种::血液肿瘤::多发性骨髓瘤",
            "癌种::妇科肿瘤", "癌种::头颈癌",
            "靶点::EGFR", "靶点::ALK", "靶点::KRAS", "靶点::HER2",
            "治疗::免疫治疗::PD-1", "治疗::免疫治疗::PD-L1",
            "治疗::靶向治疗::TKI", "治疗::靶向治疗::ADC",
            "研究类型::RCT::3期", "研究类型::RCT::2期",
            "终点::OS", "终点::PFS",
        ]:
            tid = tag_map.get(tag_path)
            if tid:
                db.add(UserSubscription(id=uid(), user_id=demo.id, tenant_id=tenant.id,
                          tag_id=tid, match_mode="standard"))
        await db.commit()
    print("  Demo user: demo@test.cn / 123456 (订阅 26 个标签，覆盖主要癌种/治疗/研究类型)")

    # 平台管理员（内置账号，无需注册）
    admin = User(id=uid(), email="admin@scilit.cn", hashed_password=hash_password("admin123"),
                  display_name="平台管理员", platform_role="platform_owner")
    db.add(admin)
    print("  Platform admin: admin@scilit.cn / admin123 (platform_owner)")

    # Demo activity data (saves, notes, reads)
    lit_ids = (await db.execute(select(GlobalLiterature.id).limit(12))).scalars().all()
    for i, lid in enumerate(lit_ids[:8]):
        db.add(UserLiterature(id=uid(), user_id=demo.id, literature_id=lid, reading_status="completed" if i<5 else "reading", rating=4 if i<3 else (3 if i<6 else None)))
    notes_text = ["联合方案OS获益显著，需权衡增加的毒性。对年轻、PS评分好的患者优先推荐。",
                  "入组标准严格，注意与真实世界的差异。结论可推广性需慎重。",
                  "T-DXd在HER2低表达中的突破，应重新审视我们的HER2检测报告阈值。",
                  "ctDNA指导辅助化疗的思路新颖，目前成本较高，普及尚需时日。"]
    for i, lid in enumerate(lit_ids[:4]):
        db.add(UserNote(id=uid(), user_id=demo.id, literature_id=lid, content=notes_text[i], is_private=(i%2==0)))
    from app.models.interaction import UserFeed
    for i, lid in enumerate(lit_ids[:10]):
        feed = (await db.execute(select(UserFeed).where(UserFeed.user_id==demo.id, UserFeed.literature_id==lid))).scalar()
        if feed: feed.is_read = (i<7); feed.read_at = datetime.now(UTC) if i<7 else None
    await db.commit()
    print("  Demo activity: 8 saves + 4 notes + 7 reads")

    # Second tenant to make dashboards richer
    t2 = Tenant(id=uid(), name="北京协和医院肿瘤内科", slug="pumch-onco", hospital_name="北京协和医院", department_name="肿瘤内科", is_personal=False)
    db.add(t2)
    u2 = User(id=uid(), email="zhang@pumch.cn", hashed_password=hash_password("123456"), display_name="张教授", title="科主任")
    db.add(u2)
    await db.flush()
    db.add(UserTenant(id=uid(), user_id=u2.id, tenant_id=t2.id, role="owner", is_default=True))
    await db.commit()
    print("  Bonus: 2nd tenant + Zhang professor")

    # 新药审批种子数据
    lung_tag = tag_map.get("癌种::肺癌")
    breast_tag = tag_map.get("癌种::乳腺癌")
    liver_tag = tag_map.get("癌种::肝癌::肝细胞癌")
    mm_tag = tag_map.get("癌种::血液肿瘤::多发性骨髓瘤")
    gastric_tag = tag_map.get("癌种::胃癌")
    melanoma_tag = tag_map.get("癌种::黑色素瘤")
    drugs = [
        ("Tagrisso", "osimertinib", "EGFR", "EGFR突变晚期NSCLC一线+辅助", "FDA", "new_drug", date(2024,2,16), lung_tag, "NCT04035486", 39000101),
        ("Imfinzi", "durvalumab", "PD-L1", "不可切除III期NSCLC巩固治疗", "NMPA", "expanded_indication", date(2024,6,10), lung_tag, "NCT02125461", 39000114),
        ("Enhertu", "trastuzumab deruxtecan", "HER2", "HER2低表达转移性乳腺癌", "FDA", "new_drug", date(2024,8,5), breast_tag, "NCT04494425", 39000103),
        ("Trodelvy", "sacituzumab govitecan", "TROP2", "HR+/HER2-晚期乳腺癌", "FDA", "expanded_indication", date(2023,2,3), breast_tag, "NCT03901339", 39000116),
        ("Imdelltra", "tarlatamab", "DLL3/CD3", "广泛期SCLC后线治疗", "FDA", "new_drug", date(2024,5,16), lung_tag, "NCT05060016", None),
        ("Tecvayli", "teclistamab", "BCMA/CD3", "RRMM后线治疗", "FDA", "new_drug", date(2022,10,25), mm_tag, "NCT04557098", 39000110),
        ("Tevimbra", "tislelizumab", "PD-1", "ESCC二线治疗", "NMPA", "new_drug", date(2024,3,20), gastric_tag, "NCT03430843", 39000105),
        ("Opdualag", "nivolumab+relatlimab", "PD-1+LAG-3", "不可切除/转移性黑色素瘤", "FDA", "new_drug", date(2022,3,18), melanoma_tag, "NCT03470922", 39000113),
        ("Imjudo + Imfinzi", "tremelimumab+durvalumab", "CTLA-4+PD-L1", "不可切除HCC一线", "FDA", "new_drug", date(2022,10,21), liver_tag, "NCT03298451", 39000138),
    ]
    for dn, gn, target, ind, agency, at, ad, ct, nct, pmid in drugs:
        db.add(DrugApproval(id=uid(), drug_name=dn, generic_name=gn, target=target, indication=ind,
                             approval_agency=agency, approval_type=at, approval_date=ad,
                             cancer_type_tag_id=ct, pivotal_trial_nct=nct, pivotal_trial_pmid=pmid))
    print(f"  Drug approvals: {len(drugs)} records")

    # 指南种子数据
    guidelines = [
        ("NCCN", lung_tag, "2025.v3", date(2025,5,1), "osimertinib+chemo 1类推荐; amivantamab+lazertinib新增; 围术期免疫治疗扩展"),
        ("NCCN", breast_tag, "2025.v2", date(2025,3,15), "T-DXd HER2低表达1类; sacituzumab govitecan HR+后线1类"),
        ("NCCN", liver_tag, "2025.v1", date(2025,2,1), "atezo+bev 1L; durva+treme 1L; lenva+pembro 1L"),
        ("CSCO", lung_tag, "2025", date(2025,4,20), "更新驱动基因阳性NSCLC治疗路径; 新增国产PD-1一线推荐"),
        ("CSCO", gastric_tag, "2025", date(2025,3,10), "胃癌免疫治疗一线推荐扩展; 靶向治疗新增CLDN18.2"),
        ("ESMO", lung_tag, "2025", date(2025,6,1), "EGFR突变一线方案更新; 寡转移SBRT证据升级"),
        ("NHC", liver_tag, "2024", date(2024,12,15), "原发性肝癌诊疗指南(2024版) - PD-1/PD-L1联合TKI一线首选"),
    ]
    for src, ct, ver, pd, summary in guidelines:
        gv = GuidelineVersion(id=uid(), guideline_source=src, cancer_type_tag_id=ct,
                               version=ver, publish_date=pd, change_summary_zh=summary)
        db.add(gv)
    await db.flush()
    print(f"  Guidelines: {len(guidelines)} records")

    # 指南证据链种子数据
    guid_ev_map = {
        ("NCCN", "2025.v3"): [
            ("39000101", "Osimertinib+化疗作为EGFR突变NSCLC一线首选（1类推荐）", "1A", "1L"),
            ("39000115", "Amivantamab+Lazertinib作为EGFR突变NSCLC一线可选方案", "1A", "1L"),
            ("39000106", "辅助Alectinib用于ALK阳性NSCLC（1类推荐）", "1A", "adjuvant"),
        ],
        ("NCCN", "2025.v2"): [
            ("39000103", "T-DXd用于HER2低表达转移性乳腺癌（1类推荐）", "1A", "2L"),
            ("39000108", "CDK4/6抑制剂+ET作为HR+/HER2- mBC一线首选", "1A", "1L"),
        ],
    }
    evidence_count = 0
    for (src, ver), ev_list in guid_ev_map.items():
        gv = (await db.execute(select(GuidelineVersion).where(
            GuidelineVersion.guideline_source == src, GuidelineVersion.version == ver))).scalar()
        if not gv: continue
        for pmid_str, rec, level, line in ev_list:
            lit = (await db.execute(select(GlobalLiterature).where(GlobalLiterature.pmid == int(pmid_str)))).scalar()
            if lit:
                db.add(GuidelineEvidence(id=uid(), guideline_version_id=gv.id, literature_id=lit.id,
                         recommendation=rec, recommendation_level=level, treatment_line=line))
                evidence_count += 1
    print(f"  Guideline evidence: {evidence_count} links")

    await db.commit()

    # 生成 Feed（复用同一个 session）
    print("  Generating feeds...")
    async with async_session() as db2:
        feeds = await generate_all_feeds(db2)
    print(f"  Feeds generated: {feeds}")
    print("=== Done ===")

if __name__ == '__main__':
    asyncio.run(main())
